Brief Report: Highly Active Antiretroviral Therapy Mitigates Liver Disease in HIV Infection

J Acquir Immune Defic Syndr. 2016 Jul 1;72(3):319-23. doi: 10.1097/QAI.0000000000000981.

Abstract

To determine the impact of highly active antiretroviral therapy (HAART) on liver disease, we analyzed changes in the aspartate aminotransferase to platelet ratio index (APRI) pre- and post-HAART initiation among 441 HIV-monoinfected and 53 HIV-viral hepatitis-coinfected men. Before HAART, APRI increased 17% and 34% among the HIV-monoinfected and coinfected men, respectively. With HAART initiation, APRI decreased significantly in men who achieved HIV RNA of <500 copies per milliliter: 16% for HIV-monoinfected and 22% for coinfected men. Decreases in APRI were dependent on HIV suppression. This protective effect of HAART decreased after 2 years, particularly in the HIV-monoinfected men.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

MeSH terms

  • Alanine Transaminase / blood
  • Antiretroviral Therapy, Highly Active*
  • Aspartate Aminotransferases / blood
  • CD4 Lymphocyte Count
  • Coinfection
  • Disease Progression
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology*
  • Homosexuality, Male
  • Humans
  • Liver / drug effects*
  • Liver / pathology*
  • Liver / virology
  • Liver Diseases / drug therapy*
  • Liver Diseases / epidemiology*
  • Liver Diseases / pathology
  • Liver Diseases / virology
  • Male
  • Prospective Studies
  • Viral Load

Substances

  • Aspartate Aminotransferases
  • Alanine Transaminase